Vontobel Holding Ltd. Has $80.23 Million Holdings in Abbott Laboratories $ABT

Vontobel Holding Ltd. decreased its holdings in Abbott Laboratories (NYSE:ABT) by 67.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 884,233 shares of the healthcare product maker’s stock after selling 1,860,540 shares during the period. Vontobel Holding Ltd.’s holdings in Abbott Laboratories were worth $80,235,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ABT. J. Stern & Co. LLP increased its holdings in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank bought a new position in Abbott Laboratories during the fourth quarter worth $2,938,892,000. Arrowstreet Capital Limited Partnership boosted its position in Abbott Laboratories by 217.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after purchasing an additional 3,780,402 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Abbott Laboratories by 303.0% in the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock valued at $454,784,000 after purchasing an additional 3,330,368 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Abbott Laboratories Stock Down 0.0%

ABT stock opened at $116.62 on Monday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The business has a 50-day simple moving average of $100.08 and a 200 day simple moving average of $99.98. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market cap of $201.80 billion, a PE ratio of 37.74, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ABT shares. BTIG Research raised their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. JPMorgan Chase & Co. lifted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Finally, Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research note on Thursday, August 13th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $118.67.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.